An official website of the United States government
Magnetic resonance imaging (MRI) is a routinely used imaging technique in medical diagnostics. To enhance the quality of MR images, contrast agents (CAs) are used, which account for nearly 40% of MRI exams in the clinic globally. The most used CAs are gadolinium-based CAs (GBCAs) but the use of GBCAs has been linked with metal-deposition in vital organs. Gadolinium deposition has been shown to be correlated with nephrogenic systemic fibrosis, a fibrosis of the skin and internal organs. Therefore, there is an unmet need for a new CA alternative to GBCAs for T 1 -weighted Ce-MRI. Herein, we designed paramagnetic ferric iron( iii ) ion-chelated poly(lactic- co -glycolic)acid nanoparticle formulation and routinely examined their application in Ce-MRI using clinical and ultra-high-field MRI scanners. Nanoparticles were monodispersed and highly stable at physiological pH over time with the hydrodynamic size of 130 ± 12 nm and polydispersity index of 0.231 ± 0.026. The T 1 -contrast efficacy of the nanoparticles was compared with commercial agent gadopentetate dimeglumine, called Magnevist®, in aqueous phantoms in vitro and then validated in vivo by visualizing an angiographic map in a clinical MRI scanner. Relaxivities of the nanoparticles in an aqueous environment were r 1 = 10.59 ± 0.32 mmol −1 s −1 and r 1 = 3.02 ± 0.14 mmol −1 s −1 at 3.0 T and 14.1 T measured at room temperature and pH 7.4, respectively. The clinically relevant magnetic field relaxivity is three times higher compared to the Magnevist®, a clinical GBCA, signifying its potential applicability in clinical settings. Moreover, iron is an endogenous metal with known metabolic safety, and the polymer and phospholipids used in the nanoconstruct are biodegradable and biocompatible components. These properties further put the proposed T 1 agent in a promising position in contrast-enhanced MRI of patients with any disease conditions.
more »
« less
Iron oxide nanoparticles as positive T1 contrast agents for low-field magnetic resonance imaging at 64 mT
Abstract We have investigated the efficacy of superparamagnetic iron oxide nanoparticles (SPIONs) as positive T1contrast agents for low-field magnetic resonance imaging (MRI) at 64 millitesla (mT). Iron oxide-based agents, such as the FDA-approved ferumoxytol, were measured using a variety of techniques to evaluate T1contrast at 64 mT. Additionally, we characterized monodispersed carboxylic acid-coated SPIONs with a range of diameters (4.9–15.7 nm) in order to understand size-dependent properties of T1contrast at low-field. MRI contrast properties were measured using 64 mT MRI, magnetometry, and nuclear magnetic resonance dispersion (NMRD). We also measured MRI contrast at 3 T to provide comparison to a standard clinical field strength. SPIONs have the capacity to perform well as T1contrast agents at 64 mT, with measured longitudinal relaxivity (r1) values of up to 67 L mmol−1 s−1, more than an order of magnitude higher than corresponding r1values at 3 T. The particles exhibit size-dependent longitudinal relaxivities and outperform a commercial Gd-based agent (gadobenate dimeglumine) by more than eight-fold at physiological temperatures. Additionally, we characterize the ratio of transverse to longitudinal relaxivity, r2/r1and find that it is ~ 1 for the SPION based agents at 64 mT, indicating a favorable balance of relaxivities for T1-weighted contrast imaging. We also correlate the magnetic and structural properties of the particles with models of nanoparticle relaxivity to understand generation of T1contrast. These experiments show that SPIONs, at low fields being targeted for point-of-care low-field MRI systems, have a unique combination of magnetic and structural properties that produce large T1relaxivities.
more »
« less
- Award ID(s):
- 2038046
- PAR ID:
- 10432536
- Publisher / Repository:
- Nature Publishing Group
- Date Published:
- Journal Name:
- Scientific Reports
- Volume:
- 13
- Issue:
- 1
- ISSN:
- 2045-2322
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Abstract Early studies suggested that FeIIIcomplexes cannot compete with GdIIIcomplexes as T1MRI contrast agents. Now it is shown that one member of a class of high‐spin macrocyclic FeIIIcomplexes produces more intense contrast in mice kidneys and liver at 30 minutes post‐injection than does a commercially used GdIIIagent and also produces similar T1relaxivity in serum phantoms at 4.7 T and 37 °C. Comparison of four different FeIIImacrocyclic complexes elucidates the factors that contribute to relaxivity in vivo including solution speciation. Variable‐temperature17O NMR studies suggest that none of the complexes has a single, integral inner‐sphere water that exchanges rapidly on the NMR timescale. MRI studies in mice show large in vivo differences of three of the FeIIIcomplexes that correspond, in part, to their r1relaxivity in phantoms. Changes in overall charge of the complex modulate contrast enhancement, especially of the kidneys.more » « less
-
Liposomes containing high-spin Fe(iii ) coordination complexes were prepared towards the production of T 1 MRI probes with improved relaxivity. The amphiphilic Fe( iii) complexes were anchored into the liposome with two alkyl chains to give a coordination sphere containing mixed amide and hydroxypropyl pendant groups. The encapsulated complex contains a macrocyclic ligand with three phosphonate pendants, [Fe(NOTP)] 3−, which was chosen for its good aqueous solubility. Four types of MRI probes were prepared including those with intraliposomal Fe(iii) complex (LipoA) alone, amphiphilic Fe(iii) complex (LipoB), both intraliposomal and amphiphilic complex (LipoC) or micelles formed with amphiphilic complex. Water proton relaxivities r 1 and r 2 were measured and compared to a small molecule macrocyclic Fe(iii) complex containing similar donor groups. Micelles of the amphiphilic Fe( iii) complex had proton relaxivity values ( r 1 = 2.6 mM−1 s −1 ) that were four times higher than the small hydrophilic analog. Liposomes with amphiphilic Fe(iii) complex (LipoB) have a per iron relaxivity of 2.6 mM −1 s −1 at pH 7.2, 34 °C at 1.4 T whereas liposomes containing both amphiphilic and intraliposomal Fe(iii) complexes (lipoC) have r 1 of 0.58 mM −1 s −1 on a per iron basis consistent with quenching of the interior Fe(iii) complex relaxivity. Liposomes containing only encapsulated [Fe(NOTP)]3− have a lowered r 1 of 0.65 mM−1s −1 per iron complex. Studies show that the biodistribution and clearance of the different types liposomal nanoparticles differ greatly. LipoB is a blood pool agent with a long circulation time whereas lipoC is cleared more rapidly through both renal and hepatobiliary pathways. These clearance differences are consistent with lower stability of LipoC compared to LipoB.more » « less
-
Magnetic nanoparticles are robust contrast agents for MRI and often produce particularly strong signal changes per particle. Leveraging these effects to probe cellular- and molecular-level phenomena in tissue can, however, be hindered by the large sizes of typical nanoparticle contrast agents. To address this limitation, we introduce single-nanometer iron oxide (SNIO) particles that exhibit superparamagnetic properties in conjunction with hydrodynamic diameters comparable to small, highly diffusible imaging agents. These particles efficiently brighten the signal in T 1 -weighted MRI, producing per-molecule longitudinal relaxation enhancements over 10 times greater than conventional gadolinium-based contrast agents. We show that SNIOs permeate biological tissue effectively following injection into brain parenchyma or cerebrospinal fluid. We also demonstrate that SNIOs readily enter the brain following ultrasound-induced blood–brain barrier disruption, emulating the performance of a gadolinium agent and providing a basis for future biomedical applications. These results thus demonstrate a platform for MRI probe development that combines advantages of small-molecule imaging agents with the potency of nanoscale materials.more » « less
-
Abstract Millions of people a year receive magnetic resonance imaging (MRI) contrast agents for the diagnosis of conditions as diverse as fatty liver disease and cancer. Gadolinium chelates, which provide preferredT1contrast, are the current standard but face an uncertain future due to increasing concerns about their nephrogenic toxicity as well as poor performance in high‐field MRI scanners. Gadolinium‐containing nanocrystals are interesting alternatives as they bypass the kidneys and can offer the possibility of both intracellular accumulation and active targeting. Nanocrystal contrast performance is notably limited, however, as their organic coatings block water from close interactions with surface Gadoliniums. Here, these steric barriers to water exchange are minimized through shape engineering of plate‐like nanocrystals that possess accessible Gadoliniums at their edges. Sulfonated surface polymers promote second‐sphere relaxation processes that contribute remarkable contrast even at the highest fields (r1= 32.6 × 10−3mGd−1s−1at 9.4 T). These noncytotoxic materials release no detectable free Gadolinium even under mild acidic conditions. They preferentially accumulate in the liver of mice with a circulation half‐life 50% longer than commercial agents. These features allow theseT1MRI contrast agents to be applied for the first time to the ex vivo detection of nonalcoholic fatty liver disease in mice.more » « less
